tirzepatide chronic kidney disease trial 𧬠New data from the SUMMIT reveals that long-term (Zepbound) may significantly improve function in patients with obesity, kidney (CKD), and heart failure with preserved ejection fraction ( Kidney Outcomes in SURPASS: Exploring
Description
Why you still need fat Fat is not the enemy
For researchers whose metabolic profiles include kidney function concerns alongside weight management goals, dulaglutide fills a specific clinical niche that tirzepatide does not yet have formal data to support
In July 2024, a report released by Morgan Stanley showed that by 2030, Amgen (67%), BMS (63%), and Merck (56%) will face the highest revenue risks
They may prefer steady progress with a medication they tolerate well
pharmacies and third-party tested for quality and safety
Katona B
